Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard o

OMO-103 in Phase 1b clinical trial Peptomyc logo Peptomyc logo BARCELONA, Spain, July 27, 2023 (Newswire.com) - Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for can...

Related Keywords

Zaragoza ,Baja California ,Mexico ,Spain ,Hospitalet ,Comunidad Autonoma De Cataluna ,Barcelona ,Hebron ,Israel General ,Israel ,Madrid ,Manuela Niewel ,Gregorio Mara ,Mariona Calvo ,Miguel Servet ,Teresa Macarulla ,Laura Soucek ,Roberto Pazo ,Catalan Institute Of Research ,Hebron Institute Of Oncology ,Pancreatic Ductal Adenocarcinoma ,Chief Medical Officer ,Hebron Institute ,Hospital Gregorio Mara ,Hospital Miguel Servet ,Catalan Institute ,Advanced Studies ,Contact Information ,Peptomyc Announces ,Its Phase ,Trial Testing ,Combination With Standard ,